Bronchodilator treatment of stable COPD: Long-acting anticholinergics

European Respiratory Review

Volumn 14, Issue 94, 2005, Pages 23-31

  Vincken, W ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Anticholinergic agents; Bronchodilators; Chronic obstructive pulmonary disease; Tiotropium bromide; Treatment

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; IPRATROPIUM BROMIDE; LONG ACTING DRUG; SALMETEROL; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG HALF LIFE; DRUG POTENCY; DRUG TOLERABILITY; DYSPNEA; EXERCISE; HOSPITALIZATION; HUMAN; QUALITY OF LIFE; REVIEW; XEROSTOMIA;

EID: 24644480223     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09058180.05.00009403     Document Type: Review

References (60)

1. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management and prevention of COPD. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276, and 2003 update.
2. Barnes PJ. Neural control in human airways in health and disease. Am Rev Respir Dis 1986; 134: 1289-1314.
3. Barnes PJ. Muscarinic receptor subtypes in airways. Life Sci 1993; 52: 521-527.
4. Eglen RM, Hegde SS, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 1996; 48: 531-565.
5. Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstruction due to emphysema. New Engl J Med 1984; 311: 421-425.
6. Ashutosh K, Lang H. Comparison between long-term treatment of chronic bronchitic airway obstruction with ipratropium bromide and metaproterenol. Ann Allergy 1984; 53: 401-406.
7. Braun SR, Mc Kenzie WN, Copeland C, et al. A comparison of the effect of ipratropium and albuterol in the treatment of chronic obstructive airway disease. Arch Intern Med 1989; 149: 544-547.
8. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 542-549.
9. Teramoto S, Fukuchi Y. Improvements in exercise capacity and dyspnea by inhaled anticholinergic drug in elderly patients with chronic obstructive pulmonary disease. Age and Ageing 1995; 24: 278-282.
10. Oga T, Nishimura K, Tsukino M, et al. The effects of oxitropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1897-1901.
11. Pavia D, Bateman JR, Sheahan NF, et al. Effect of ipratropium bromide on mucociliary clearance and pulmonary function in reversible airways obstruction. Thorax 1979; 34: 501-507.
12. Jenkins CR, Chow CM, Fisher BL, et al. Ipratropium bromide and fenoterol by aerosolized solution. Br J Clin Pharmacol 1982; 14: 113-115.
13. Grassi V, Bruni B, Peccini F, et al. Acute on chronic comparative effects of a combination of fenoterol-ipratropium bromide and terbutaline in patients with chronic obstructive lung disease. Respiration 1986; 50: Suppl. 2, 226-231.
14. Barnabe R, Pirrelli M, Rossi M. Combined inhalation of fenoterol and ipratropium bromide in long-term therapy of chronic reversible airway obstruction. Respiration 1986; 50: Suppl. 2, 232-235.
15. Frith PA, Jenner B, Dangerfield R, et al. Oxitropium bromide. Dose-response and time-response study of a new anticholinergic bronchodilator drug. Chest 1986;89:249-253.
16. Combivent Inhalation Aerosol Study Group. Chronic obstructive pulmonary disease a combination of ipratropium and albuterol is more effective than either agent alone: an 85 day multicenter trial. Chest 1994; 105: 1411-1419.
17. Wilson JD, Serby CW, Menjoge SS, et al. The efficacy and safety of combination bronchodilator therapy. Eur Respir Rev 1996; 6: 39, 286-289.
18. Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared to ipratropium alone and albuterol alone in COPD. Chest 1999; 115: 635-641.
19. Benayoun S, Ernst P, Suissa S. The impact of combined inhaled bronchodilator therapy in the treatment of COPD. Chest 2001; 119: 85-92.
20. American Thoracic Society Statement. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-S120.
21. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1398-1420.
22. Tashkin DP. Multiple dose regimens: impact on compliance. Chest 1995; 107: 176S-182S.
23. Mellins RB, Evans D, Zimmerman B, et al. Patient compliance: are we wasting our time and don't know it? Am Rev Respir Dis 1992; 146: 1376-1377.
24. Ulrik CS. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomized, double-blind, placebo controlled, crossover study. Thorax 1995; 50: 750-756.
25. Grove A, Lipworth BJ, Reid P, et al. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax 1996; 51: 689-693.
26. Boyd G, Morice AH, Pounsford JC, et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10: 815-821.
27. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-1289.
28. Cazzola M, Matera MG, Santangelo G, et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995; 89: 357-362.
29. Benhamou D, Cuvelier A, Muir JF, et al. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil® Aerolizer™) with salbutamol (Ventodisk™). Respir Med 2001; 95: 817-821.
30. Kottakis J, Della Cioppa G, Creemers J, et al. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can Respir J 2002; 9: 107-115.
31. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-965.
32. Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778-784.
33. Van Noord JA, de Munck DR, Bantje TA, et al Long-term treatment of COPD with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15: 878-885.
34. D'Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. In patients with COPD treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium. A 3-week, randomized, double-blind, within-patient, multicenter study. Chest 2001; 119: 1347-1356.
35. Liesker JJW, Van De Velde V, Meysman M, et al. Effects of formoterol (Oxis® Turbohaler®) and ipratropium on exercise capacity in patients with COPD. Respir Med 2002; 96: 559-566.
36. Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva®): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999; 64: 457-464.
37. Takahashi T, Belvisi MG, Patel H, et al. Effect of BA679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med 1994; 150: 1640-1645.
38. Disse B, Reichl R, Speck G, et al. BA679 BR, a novel long-acting anticholinergic bronchodilator: predicted and clinical aspects. Life Sci 1993; 52: 537-544.
39. Maesen FPV, Smeets JJ, Costongs MAL, et al. BA679 BR, a new long-acting anti-muscarinic bronchodilator: a pilot dose escalation study. Eur Respir J 1993; 6: 1031-1036.
40. Maesen FPV, Smeets JJ, Sledsens TJH, et al. Tiotropium bromide, a new long-acting anti-muscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1995; 8: 1506-1513.
41. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1136-1142.
42. Van Noord JA, Smeets JJ, Custers FLJ, et al. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 639-644.
43. Chodosh S, Flanders JS, Kesten S, et al. Effective delivery of particles with the Handihaler® dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. Journal of Aerosol Medidne 2001; 14: 309-315.
44. Casaburi R, Briggs DD, Donohue JF, et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD. A 13-week multicenter trial. Chest 2000; 118: 1294-1302.
45. Van Noord JA, Bantje TA, Eland ME, et al. A randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000; 55: 289-294.
46. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily tiotropium in COPD. Eur Respir J 2002; 19: 217-224.
47. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 2002; 19: 209-216.
48. Mahler DA, Weinber DH, Wells CK, et al The measurement of dyspnea: contents, interobserver agreement and physiological correlates of 2 new clinical indexes. Chest 1984; 85: 751-758.
49. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. Am Rev Respir Dis 1992; 145: 1321-1327.
50. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404.
51. Oostenbrink JB, Rutten-van Mölken MPMH, van Noord JA, Vincken W. One-year cost-effectiveness of tiotropium vs. ipratropium to treat COPD. Eur Respir J 2004; 23: 241-249.
52. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.
53. Van Noord JA, Aumann J, Janssens E, et al. Comparison of once-daily tiotropium, twice-daily formoterol and the free combination once-daily in patients with COPD. ATS 2003, Seattle. Am J Respir Crit Care Med 2003; 167: A320.
54. Van Noord JA, Aumann J, Janssens E, et al. Tiotropium maintenance therapy in patients with COPD and the 24-h spirometric benefit of adding once or twice daily formoterol during 2-week treatment periods. ATS 2003, Seattle. Am J Respir Crit Care Med 2003; 167: A320.
55. Belman M, Botnick WC, Shin JW. Inhaled bronchodilatorsreduce dynamic hyperinflation during exercise in patients with COPD. Am J Respir Crit Care Med 1996; 153: 967-975.
56. O'Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-840.
57. Celli B, Zuwallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743-1748.
58. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEVl decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 358-364.
59. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
60. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004; 125: 249-259.